We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics
ALDX

26 hedge funds and large institutions have $34.7M invested in Aldeyra Therapeutics in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

8% more funds holding

Funds holding: 24 → 26 (+2)

3.08% less ownership

Funds ownership: 52.23% → 49.16% (-3.1%)

8% less capital invested

Capital invested by funds: $38M → $34.7M (-$3.22M)

Holders
26
Holders Change
+2
Holders Change %
+8.33%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
8
Reduced
7
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
6CM
683 Capital Management
New York
+$2.41M
2
SFM
Sphera Funds Management
Israel
+$954K
3
HP
Hikari Power
Japan
+$323K
4
Renaissance Technologies
Renaissance Technologies
New York
+$133K
5
VKH
Virtu KCG Holdings
New York
+$103K

Top Sellers

1
AIC
AWM Investment Company
New York
-$4.56M
2
BC
Boxer Capital
California
-$1.46M
3
SM
Sabby Management
Florida
-$377K
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$235K
5
Deutsche Bank
Deutsche Bank
Germany
-$39K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$13.4M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$7.78M -$235K -51,000 -3%
SFM
3
Sphera Funds Management
Israel
$4.12M +$954K +207,431 +31%
6CM
4
683 Capital Management
New York
$2.44M +$2.41M +525,093 New
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$2.21M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.43M +$43.3K +9,407 +3%
KCM
7
Knoll Capital Management
Florida
$583K – – –
HP
8
Hikari Power
Japan
$507K +$323K +70,196 +186%
Millennium Management
9
Millennium Management
New York
$467K -$13.3K -2,885 -3%
SM
10
Sabby Management
Florida
$454K -$377K -81,923 -46%
WMSA
11
Weiss Multi-Strategy Advisers
New York
$288K -$13.8K -3,000 -5%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$271K +$13.6K +2,966 +5%
Renaissance Technologies
13
Renaissance Technologies
New York
$257K +$133K +29,000 +110%
BlackRock
14
BlackRock
New York
$184K +$20.5K +4,449 +13%
VKH
15
Virtu KCG Holdings
New York
$104K +$103K +22,431 New
Northern Trust
16
Northern Trust
Illinois
$70K – – –
AAP
17
Ardsley Advisory Partners
Connecticut
$68K +$66.9K +14,552 New
Bank of America
18
Bank of America
North Carolina
$42K +$4.6K +1,000 +13%
Morgan Stanley
19
Morgan Stanley
New York
$13K +$14 +3 +0.1%
PCM
20
Prelude Capital Management
New York
$11K +$11.3K +2,451 New
NFG
21
Next Financial Group
Texas
$9K +$9.2K +2,000 New
SEI Investments
22
SEI Investments
Pennsylvania
$8K +$8.28K +1,800 New
UBS Group
23
UBS Group
Switzerland
$5K -$3.31K -721 -39%
Manulife (Manufacturers Life Insurance)
24
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K -$326 -71 -8%
AIC
25
AWM Investment Company
New York
– -$4.56M -912,610 Closed
1
2

ALDX Hedge Fund Activity: Q2 2017 in Review

26 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2017, worth a combined $34.7M — down 8.5% from $38M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ALDX positions and 5 closed out — a net gain of 2 holders — while 8 added to existing stakes and 7 trimmed.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $2.41M. The largest seller was AWM Investment Company, exiting entirely with an estimated $4.56M sold.

  • 26 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2017, up from 24 in Q1 2017.
  • Funds reported $34.7M of Aldeyra Therapeutics stock for Q2 2017, down 8.5% quarter-over-quarter.
  • 7 funds opened new Aldeyra Therapeutics positions in Q2 2017 and 5 closed out, a net change of +2 holders.
  • The largest Aldeyra Therapeutics buyer in Q2 2017 was 683 Capital Management, an estimated $2.41M added.
  • The largest Aldeyra Therapeutics seller in Q2 2017 was AWM Investment Company, an estimated $4.56M sold.

Based on aggregated 13F filings for Q2 2017.